Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.19 USD | -1.41% | -4.56% | -39.05% |
16/04 | SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update | CI |
02/04 | HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating | MT |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.